Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?
Where this comes from
- Record sourced from PubMed, PMID 27521103.
- Also identified by DOI 10.1016/j.kint.2016.06.021.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The recently published Heart Outcomes Prevention Evaluation trial (HOPE-3) demonstrated no benefit of lowering blood pressure with candesartan and hydrochlorothiazide in persons at intermediate cardiovascular risk and with adequate blood pressure control as determined by the enrolling physician. The results of Systolic Blood Pressure Intervention Trial (SPRINT) and HOPE-3 highlight the importance of considering differences in study design and patient population when interpreting the results of clinical trials.
Medical subject headings
- Antihypertensive Agents
- Cardiovascular Diseases